JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: http://goo.gl/tW6DQL
During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
See More: http://goo.gl/tW6DQL
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Table 89: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in<br />
UC 204<br />
Table 90: Kappaproct SWOT <strong>Analysis</strong>, 2014 206<br />
Table 91: <strong>Global</strong> Sales <strong>Forecast</strong>s ($m) for Kappaproct, 2012-<strong>2022</strong> 207<br />
Table 92: Key Companies in the UC <strong>Market</strong>, 2012-<strong>2022</strong> 209<br />
Table 93: J&Js UC Portfolio Assessment, 2014 213<br />
Table 94: J&Js SWOT <strong>Analysis</strong> in UC, 2014 214<br />
Table 95: AbbVies UC Portfolio Assessment, 2014 215<br />
Table 96: AbbVies UC SWOT <strong>Analysis</strong>, 2014 216<br />
Table 97: Takeda Pharmaceuticals UC Portfolio Assessment, 2014 217<br />
Table 98: Takedas UC SWOT <strong>Analysis</strong>, 2014 218<br />
Table 99: Warner Chilcotts UC Portfolio Assessment, 2014 219<br />
Table 100: Warner Chilcotts UC SWOT <strong>Analysis</strong>, 2014 220<br />
Table 101: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013 221<br />
Table 102: Salix Pharmaceuticals/Santarus UC SWOT <strong>Analysis</strong>, 2014 222<br />
Table 103: Shire Pharmaceuticals UC Portfolio Assessment, 2014 223<br />
Table 104: Shire Pharmaceuticals UC SWOT <strong>Analysis</strong>, 2014 223<br />
Table 105: Ferring Pharmaceuticals UC Portfolio Assessment, 2013 224<br />
Table 106: Ferring Pharmaceuticals UC SWOT <strong>Analysis</strong>, 2014 225<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language